Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H16O6.2C22H29N3O6S |
Molecular Weight | 1315.464 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(C=CC=C2)C(CC3=C4C=CC=CC4=CC(C(O)=O)=C3O)=C1O.[H][C@]56SC(C)(C)[C@@H](N5C(=O)[C@H]6NC(=O)[C@H](N)C7=CC=CC=C7)C(=O)OCOC(=O)C(C)(C)C.[H][C@]89SC(C)(C)[C@@H](N8C(=O)[C@H]9NC(=O)[C@H](N)C%10=CC=CC=C%10)C(=O)OCOC(=O)C(C)(C)C
InChI
InChIKey=RYPIBFIQHKWKBM-WDPVPZODSA-N
InChI=1S/C23H16O6.2C22H29N3O6S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t;2*13-,14-,15+,18-/m.11/s1
Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMPICILLIN SODIUM Approved UseAmpicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.) |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129.5 μg/mL |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 h |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
AMPICILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (25%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
5 g 3 times / day multiple, intravenous Highest studied dose Dose: 5 g, 3 times / day Route: intravenous Route: multiple Dose: 5 g, 3 times / day Co-administed with:: Sulbactam(500 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
unhealthy, adult n = 9 Health Status: unhealthy Condition: Bacterial infections Age Group: adult Sex: M+F Population Size: 9 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
Other AEs: Injection site pain... Other AEs: Injection site pain Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Other AEs: Injection site pain, Creatine phosphokinase increased... Other AEs: Injection site pain (grade 3-4, 100%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40Creatine phosphokinase increased (100%) |
2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Other AEs: Injection site pain, Rash... Other AEs: Injection site pain (1%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160Rash (1%) Diarrhea (5%) Fatigue (3%) Chills (1%) Headache (1%) AST increased (3%) Bilirubin increased (1%) Creatinine increased (1%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Other AEs: Chest pain, Flatulence... Other AEs: Chest pain (5%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53Flatulence (5%) Diarrhea (10%) Injection site pain (5%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Other AEs: Injection site pain, Phlebitis... Other AEs: Injection site pain (0.8%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57Phlebitis (5.3%) Chest pain (0.8%) Diarrhea (6.8%) Vomiting (0.8%) Retention of urine (0.8%) Rash (0.8%) Epistaxis (0.8%) Edema (0.8%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Other AEs: Thrombophlebitis, Nausea... Other AEs: Thrombophlebitis (6.7%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155Nausea (6.7%) Diarrhea (6.7%) Rash (6.7%) Blood eosinophils increased (6.7%) AST increased (6.7%) ALT increased (13.3%) GGT increased (13.3%) Alkaline phosphatase increased (6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin rash | 25% Disc. AE |
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Injection site pain | 0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
|
Creatine phosphokinase increased | 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Injection site pain | grade 3-4, 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Bilirubin increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Chills | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Creatinine increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Headache | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Injection site pain | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Rash | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
AST increased | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Fatigue | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 5% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 10% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Flatulence | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Injection site pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Edema | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Epistaxis | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Injection site pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Rash | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Retention of urine | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Vomiting | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Phlebitis | 5.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Diarrhea | 6.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
ALT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
GGT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
AST increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Alkaline phosphatase increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Blood eosinophils increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Diarrhea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Nausea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Rash | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Thrombophlebitis | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 2.0 |
yes [Inhibition 1000 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Fresh vs aged benzylpenicillin on non-IgE responses in mice. | 1998 Jan |
|
Immunologic response to different determinants of benzylpenicillin, amoxicillin, and ampicillin. Comparison between urticaria and anaphylactic shock. | 1999 Sep |
|
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA. | 2001 |
|
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection. | 2001 |
|
Effect of granulocyte-macrophage colony-stimulating factor on treatment of acute osteomyelitis. An experimental investigation in rats. | 2001 |
|
[Clinical characteristics of beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR) in respiratory tract]. | 2001 Apr |
|
[Beta-lactamase negative ampicillin-resistant Haemophilus influenzae(BLNAR)]. | 2001 Apr |
|
[Beta-lactam and macrolide resistance in Streptococcus pneumoniae]. | 2001 Apr |
|
Novel quantitative assays for estimating the antimicrobial activity of fresh garlic juice. | 2001 Feb |
|
An unusual blood culture isolate in a 15-year-old boy. | 2001 Feb |
|
Resistance patterns of non-O157 Shiga toxin-producing Escherichia coli (STEC) strains isolated from animals, food and asymptomatic human carriers in Switzerland. | 2001 Feb |
|
Shigella and Salmonella strains isolated from children under 5 years in Gaborone, Botswana, and their antibiotic susceptibility patterns. | 2001 Jan |
|
Synthesis and properties of dextran-linked ampicillin. | 2001 Jan |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. | 2001 Jan |
|
Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh: the randomized, double-blind, prospective trial. | 2001 Jan |
|
In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. | 2001 Jan |
|
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age]. | 2001 Jan-Feb |
|
Antibiotic-resistant bacteria in pediatric chronic sinusitis. | 2001 Mar |
|
Longitudinal surveillance of antibiotic use in the hospital. | 2001 Mar |
|
Improved agar diffusion method for detecting residual antimicrobial agents. | 2001 Mar |
|
Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. | 2001 Mar |
|
Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. | 2001 May 15 |
|
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. | 2001 Spring |
|
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. | 2001 Spring |
|
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods. | 2001 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ampicillin.html
Ampicillin Dosage and Administration
This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only.
Infections of the respiratory tract and soft tissues.
Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.
Urethritis in males due to N. gonorrhoeae.
Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.
In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.
The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate.
Bacterial Meningitis
Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.
Septicemia
Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14195635
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39030-72-3
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
5Z5TRG74EY
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
20055543
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL323354
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
C73835
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD